Cobristone is a locally acting chloride channel activator that works to stimulate and protect the mucosal barrier function. Cobristone is being developed by the Sucampo Pharmaceuticals, Inc. for the prevention of oral mucositis and for the treatment of non-erosive reflux disease (NERD), a major subtype of gastroesophageal reflux disease. The development of the drug was terminated after phase 2 clinical trials failed to meet its primary endpoints.

Salclobuzate sodium was developed as an oral absorption promoter. This compound had to “chaperone” poorly permeable payloads across the intestine. Information about the current use of this compound is not available.

AstraZeneca developed disufenton (NXY-059), a free radical trapping agent, for the treatment of ischaemic stroke and other brain injuries. Nevertheless, large clinical trial (3306 versus 1722 patients) was neutral, providing no evidence for the efficacy of disufenton sodium in patients with stroke. One study using rat cortical brain slices concluded that NXY-059 improved neuronal survival. However, another study in mouse neuroblastoma cells reported no effect. Another study reported that NXY-059 restored endothelial blood-brain. Histological analyses revealed several therapeutic advantages associated with disufenton sodium treatment following acute acoustic trauma, including reductions in inner and outer hair cell loss; reductions in acute acoustic trauma-induced loss of calretinin-positive afferent nerve fibers in the spiral lamina; and reductions in fibrocyte loss within the spiral ligament. However, AstraZeneca terminated the development program.

Nicoxamat (nicotinohydroxamic acid) is a uricosuric drug that increased urinary excretion of urea and depressed urease activity in the stomach and the colon. Patients receiving nicoxamat showed significant improvement in blood ammonia levels as compared to patients receiving neomycin. In a double-blind clinical trial, 24 patients with the advanced chronic liver disease received 1.2 g of the drug daily. Nicoxamat induced some side effects, such as mild diarrhea, constipation, and anorexia.

Furazolium, an antibacterial agent, was studied for the management of skin infections. However, information about the current use of this drug is not available.

Evacetrapib (LY2484595) is a novel benzazepine-based CETP inhibitor that has been developed at Lilly Research Laboratories. Evacetrapib inhibits CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3. On 01 Sep 2016 Eli Lilly terminates the phase III ACCENTUATE trial in Hyperlipidaemia (Adjunctive treatment) in USA and Puerto Rico (PO) due to insufficient efficacy (NCT02227784).

Eprovafen is an anti-inflammatory compound.